Mice lacking HSD17B12 exhibit fatal systemic inflammation and lipolysis, decreased numbers and sizes of lipid droplets, microsteatosis, and increased TG accumulation [68], making it a potential target for NAFLD [69]. This evidence concerns the gene HSD17B12 and metabolic dysfunction-associated steatotic liver disease.